MSME (Udyam registered) Ministry of MSME
- Category
- Small (2024-25)
- Udyam number
- UDYAM-GJ-24-0030107
Market Cap
₹10.77 Cr
LINKPH · BSE
Share Price
₹26.00
+7.22% today
Revenue
₹27.43 Cr
FY 2025-26 · +7.9% YoY
EBITDA
₹1.44 Cr
Margin 5.2%
Net Profit
₹0.07 Cr
FY 2025-26 · +106.7% YoY
ROE
0.6%
ROCE 3.4%
Debt / Equity
0.51
Interest cover 115.2x
Authorised capital
₹5 Cr
Registered with MCA
About Link Pharmachem Limited
Data last updated:
Link Pharmachem Limited is a public limited company based in Vadodara, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 28 December 1984 and has been in existence for over 42 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24230GJ1984PLC007540. Its GSTIN is 24AAACL3615M1ZL (Gujarat). It is a listed company as per MCA records. Its shares are listed on BSE: 524748.
The company has an authorised share capital of ₹5 Cr and a paid-up capital of ₹4.44 Cr. It was formerly known as Link Pharmachem Private Limited. It is led by directors including Rishikesh Satish Thakur (Managing Director) and Satish Ganpatrao Thakur (Whole-Time Director).
Its last annual general meeting (AGM) was held on 09 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 162 G.I.D.C Estate Nandesari, Vadodara, Gujarat, India – 393002.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹27.43 Cr, a growth of 7.9% compared to the previous year. For the same year it recorded a net profit of ₹7 Lakh (net margin 0.3%) and EBITDA of ₹1.44 Cr (EBITDA margin 5.2%). The net worth stands at ₹12.79 Cr (up 1% YoY). Total assets are valued at ₹20.33 Cr (up 9.2% YoY).
The company has about 84 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Link Pharma. As per MCA filings, the company has open charges of ₹19.22 Cr and satisfied charges of ₹20.51 Cr on record. Court records list 12 cases involving the company, including 6 filed by the company and 6 filed against it; 8 cases are pending. The company has 12 deals on record (12 market trades); the latest was in March 2026. Its 6 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 2 smaller; the largest is SVK Laboratories Private Limited with revenue of ₹25.79 Cr. The company has 15 MSME Form 1 returns on record between 2019 and 2024, listing 260 overdue payments to 31 micro and small suppliers.
Link Pharmachem Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-GJ-24-0030107). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website linkpharmachem.co.in.
Company details
CIN L24230GJ1984PLC007540
Registration Number 007540
Incorporation Date 28 December 1984
ROC Ahmedabad
Listing Status Listed - Listed on BSE (524748)
Company Status Active
Date of Last AGM 09 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-GJ-24-0030107
Key People
Rishikesh Satish Thakur Managing Director Satish Ganpatrao Thakur Whole-Time Director Rachna Manav Ghai Director Recognitions & Rankings of Link Pharmachem
Contact details
Link Pharmachem Limited's registered office is in Vadodara, Gujarat. Its website is linkpharmachem.co.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address162 G.I.D.C Estate Nandesari, Vadodara, Gujarat, India – 393002
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Link Pharmachem Limited, buy the company report.
Comprehensive company report
Link Pharmachem Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Link Pharmachem operates one associated brand: Link Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Developing and manufacturing services for APIs and specialty chemicals | linkpharmachem.co.in |
Business activity
The main business activity of Link Pharmachem is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Link Pharmachem Limited, buy the company report.
Financials of Link Pharmachem Limited
FY 2025-26 filings availableLink Pharmachem Limited reported revenue of ₹27.43 Cr (up 7.9% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue
₹27.43 Cr
+7.9% YoY
EBITDA
₹1.44 Cr
+1209.1% YoY
Profit After Tax
₹0.07 Cr
+106.7% YoY
Net Worth
₹12.79 Cr
+1.0% YoY
Total Assets
₹20.33 Cr
+9.2% YoY
Total Debt
₹7.31 Cr
+26.5% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 27.43 | 25.43 | 29.90 | 38.76 | 53.56 | 34.81 | 25.47 |
| Revenue growth | +7.9% | -15.0% | -22.9% | -27.6% | +53.9% | +36.7% | - |
| EBITDA | 1.44 | 0.11 | (0.65) | 2.72 | 3.53 | 2.98 | 2.60 |
| EBITDA margin | +5.3% | +0.4% | -2.2% | +7.0% | +6.6% | +8.6% | +10.2% |
| Profit before tax | 0.13 | (1.42) | (1.91) | 0.89 | 2.61 | 1.69 | 1.44 |
| Net profit | 0.07 | (1.05) | (1.44) | 0.57 | 1.43 | 1.23 | 1.61 |
| Net profit margin | +0.3% | -4.1% | -4.8% | +1.5% | +2.7% | +3.5% | +6.3% |
| EPS (₹) | 0.17 | (2.31) | (3.07) | 1.47 | 4.24 | 2.44 | 2.14 |
| Balance sheet | |||||||
| Total assets | 20.33 | 18.61 | 22.93 | 24.00 | 20.90 | 16.40 | 14.99 |
| Net worth | 12.79 | 12.66 | 13.71 | 15.04 | 14.47 | 12.56 | 11.43 |
| Total debt | 7.31 | 5.78 | 9.22 | 8.76 | 6.39 | 3.66 | 3.56 |
| Cash & bank | 0.63 | 0.06 | 0.09 | 0.20 | 0.88 | 4.86 | 2.05 |
| Net working capital | 6.70 | 6.48 | 8.69 | 9.81 | 6.46 | 6.37 | 6.02 |
| Cash flow | |||||||
| Cash from operations | 2.15 | 2.69 | (0.03) | (1.71) | (1.26) | 4.84 | 2.95 |
| Cash from investing | (2.66) | 1.53 | 0.41 | (0.08) | (4.97) | (2.16) | (1.66) |
| Cash from financing | 0.99 | (4.21) | (0.41) | 1.61 | 2.27 | (0.33) | 0.55 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.77 | 6.59 | 6.73 | 6.29 | 7.81 | 6.45 | 5.34 | 4.80 |
| Revenue growth (YoY) | +12.3% | +2.2% | +26.0% | +31.0% | -11.8% | - | - | - |
| Other income | 0.35 | 0.15 | (0.20) | 0.05 | 0.21 | 0.12 | (0.56) | 0.36 |
| Total expenses | 8.31 | 6.83 | 6.04 | 5.95 | 7.17 | 6.67 | 5.23 | 5.10 |
| EBITDA | 0.46 | (0.24) | 0.69 | 0.34 | 0.64 | (0.22) | 0.11 | (0.30) |
| EBITDA margin | +5.2% | -3.6% | +10.3% | +5.4% | +8.2% | -3.4% | +2.1% | -6.3% |
| Depreciation | 0.27 | 0.25 | 0.25 | 0.25 | 0.24 | 0.24 | 0.24 | 0.24 |
| Interest | 0.14 | 0.15 | 0.14 | 0.13 | 0.10 | 0.14 | 0.21 | 0.21 |
| Profit before tax | 0.40 | (0.49) | 0.10 | 0.01 | 0.51 | (0.48) | (0.90) | (0.39) |
| Tax | 0.07 | (0.08) | 0.04 | 0.00 | 0.11 | (0.13) | (0.22) | (0.08) |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 29 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.77 | 6.59 | 6.73 | 6.29 | 7.81 | 6.45 | 5.34 | 4.80 |
| Revenue growth (YoY) | +12.3% | +2.2% | +26.0% | +31.0% | -11.8% | - | - | - |
| Other income | 0.35 | 0.15 | (0.20) | 0.05 | 0.21 | 0.12 | (0.56) | 0.36 |
| Total expenses | 8.31 | 6.83 | 6.04 | 5.95 | 7.17 | 6.67 | 5.23 | 5.10 |
| EBITDA | 0.46 | (0.24) | 0.69 | 0.34 | 0.64 | (0.22) | 0.11 | (0.30) |
| EBITDA margin | +5.2% | -3.6% | +10.3% | +5.4% | +8.2% | -3.4% | +2.1% | -6.3% |
| Depreciation | 0.27 | 0.25 | 0.25 | 0.25 | 0.24 | 0.24 | 0.24 | 0.24 |
| Interest | 0.14 | 0.15 | 0.14 | 0.13 | 0.10 | 0.14 | 0.21 | 0.21 |
| Profit before tax | 0.40 | (0.49) | 0.10 | 0.01 | 0.51 | (0.48) | (0.90) | (0.39) |
| Tax | 0.07 | (0.08) | 0.04 | 0.00 | 0.11 | (0.13) | (0.22) | (0.08) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 27.43 | 25.43 | 29.90 | 38.76 | 53.56 | 34.81 | 25.47 |
| Revenue growth | +7.9% | -15.0% | -22.9% | -27.6% | +53.9% | +36.7% | - |
| Other income | 0.20 | 0.19 | 0.64 | (0.15) | 0.46 | 0.02 | 0.13 |
| Total expenses | 25.99 | 25.32 | 30.55 | 36.04 | 50.03 | 31.83 | 22.87 |
| Employee cost | 6.09 | 5.39 | 5.52 | 5.69 | 5.77 | 5.63 | 4.99 |
| EBITDA | 1.44 | 0.11 | (0.65) | 2.72 | 3.53 | 2.98 | 2.60 |
| EBITDA margin | +5.3% | +0.4% | -2.2% | +7.0% | +6.6% | +8.6% | +10.2% |
| Depreciation | 0.98 | 0.94 | 1.03 | 0.92 | 0.93 | 0.87 | 0.93 |
| Interest | 0.53 | 0.78 | 0.87 | 0.76 | 0.45 | 0.44 | 0.36 |
| Profit before tax | 0.13 | (1.42) | (1.91) | 0.89 | 2.61 | 1.69 | 1.44 |
| Tax | 0.06 | (0.37) | (0.55) | 0.24 | 0.74 | 0.59 | 0.49 |
| Net profit | 0.07 | (1.05) | (1.44) | 0.57 | 1.43 | 1.23 | 1.61 |
| Net profit margin | +0.3% | -4.1% | -4.8% | +1.5% | +2.7% | +3.5% | +6.3% |
| EPS (₹) | 0.17 | (2.31) | (3.07) | 1.47 | 4.24 | 2.44 | 2.14 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 |
| Reserves & surplus | 8.35 | 8.22 | 9.27 | 10.60 | 10.03 | 8.12 | 6.99 |
| Shareholders' funds (net worth) | 12.79 | 12.66 | 13.71 | 15.04 | 14.47 | 12.56 | 11.43 |
| Secured loans | 1.04 | 0.66 | 1.40 | 1.98 | 2.90 | 3.16 | 3.17 |
| Unsecured loans | 6.27 | 5.12 | 7.82 | 6.78 | 3.49 | 0.50 | 0.39 |
| Total debt | 7.31 | 5.78 | 9.22 | 8.76 | 6.39 | 3.66 | 3.56 |
| Total liabilities | 20.33 | 18.61 | 22.93 | 24.00 | 20.90 | 16.40 | 14.99 |
| Assets | |||||||
| Gross block | 18.01 | 15.95 | 15.66 | 13.88 | 12.74 | 11.74 | 11.56 |
| Net block | 10.38 | 9.28 | 9.93 | 9.00 | 8.79 | 8.71 | 8.80 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.21 | 0.00 | 0.00 |
| Investments | 2.47 | 2.06 | 2.93 | 3.64 | 4.52 | 0.03 | 0.03 |
| Inventories | 5.02 | 5.74 | 6.21 | 12.25 | 4.76 | 2.50 | 1.63 |
| Sundry debtors | 5.28 | 5.02 | 5.15 | 3.63 | 5.37 | 5.55 | 4.99 |
| Cash & bank balances | 0.63 | 0.06 | 0.09 | 0.20 | 0.88 | 4.86 | 2.05 |
| Loans & advances | 0.41 | 0.34 | 0.08 | 1.47 | 2.57 | 2.24 | 0.41 |
| Total current assets | 11.34 | 11.16 | 11.53 | 17.55 | 13.58 | 15.15 | 9.08 |
| Total current liabilities | 4.64 | 4.68 | 2.84 | 7.74 | 7.12 | 8.78 | 3.06 |
| Net working capital | 6.70 | 6.48 | 8.69 | 9.81 | 6.46 | 6.37 | 6.02 |
| Total assets | 20.33 | 18.61 | 22.93 | 24.00 | 20.90 | 16.40 | 14.99 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.06 | 0.06 | 0.09 | 0.27 | 4.22 | 1.87 | 0.02 |
| Net cash from operating activities | 2.15 | 2.69 | (0.03) | (1.71) | (1.26) | 4.84 | 2.95 |
| Net cash from investing activities | (2.66) | 1.53 | 0.41 | (0.08) | (4.97) | (2.16) | (1.66) |
| Net cash from financing activities | 0.99 | (4.21) | (0.41) | 1.61 | 2.27 | (0.33) | 0.55 |
| Net change in cash | 0.48 | 0.00 | (0.03) | (0.17) | (3.95) | 2.35 | 1.85 |
| Closing cash | 0.63 | 0.06 | 0.09 | 0.20 | 0.88 | 4.86 | 2.05 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +7.9% | -15.0% | -22.9% | -27.6% | +53.9% | +36.7% | - |
| EBITDA growth | +1209.1% | +116.9% | -123.9% | -23.0% | +18.5% | +14.6% | - |
| PBT growth | +9998.0% | +25.7% | - | -65.9% | +54.4% | +17.4% | +54.8% |
| Net income growth | +106.7% | +27.1% | -352.6% | -60.1% | +16.3% | -23.6% | - |
| Revenue CAGR (3Y) | -10.9% | -22.0% | -4.9% | +15.0% | +29.8% | +13.9% | +16.5% |
| EBITDA CAGR (3Y) | -19.1% | -68.5% | - | +1.5% | +20.5% | +2.5% | +8.8% |
| Profitability & leverage | |||||||
| Net income margin | +0.3% | -4.1% | -4.6% | +1.7% | +3.5% | +3.2% | +3.7% |
| Return on capital employed | +3.4% | -3.0% | -4.4% | +6.6% | +13.1% | +13.5% | +18.7% |
| Return on net worth | +0.6% | -7.8% | -9.5% | +3.9% | +10.7% | +9.0% | +14.8% |
| Debt / equity | 0.51 | 0.57 | 0.63 | 0.51 | 0.37 | 0.30 | 0.28 |
| Long-term debt / equity | 0.04 | 0.06 | 0.05 | 0.04 | 0.03 | 0.00 | 0.01 |
| Interest cover | 115.22 | -93.98 | -51.79 | 42.22 | 17.31 | 20.85 | 21.56 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.62 | 1.61 | 2.02 | 2.91 | 4.38 | 2.99 | 2.20 |
| Inventory turnover | 5.10 | 4.26 | 3.24 | 4.56 | 14.75 | 16.86 | 11.32 |
| Debtors turnover | 5.33 | 5.00 | 6.81 | 8.61 | 9.81 | 6.61 | 6.34 |
| EPS (₹) | 0.17 | (2.31) | (3.07) | 1.47 | 4.24 | 2.44 | 2.14 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 28.80 | 28.51 | 30.87 | 33.87 | 32.60 | 28.29 | 25.75 |
To see the full year-wise statements and ratios of Link Pharmachem Limited, buy the company report.
Board of directors of Link Pharmachem Limited
Link Pharmachem has 5 current directors and 10 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rishikesh Satish Thakur Also directs: Aarohan Chemicals Private Limited | Managing Director | 24 Jun 2020 | 6 Years 4 Months | Current |
| Satish Ganpatrao Thakur | Whole-Time Director | 28 Dec 1984 | 41 Years 10 Months | Current |
| Rachna Manav Ghai Also directs: Mindset LLP | Director | 14 Sep 2020 | 6 Years 1 Months | Current |
| Rohit Jitendraprasad Shah | Director | 09 Aug 2024 | 2 Years 2 Months | Current |
| Rangoli Saurav Gada Also directs: Shine Pharmaceuticals Limited, Medicap Healthcare Limited | Director | 09 Aug 2024 | 2 Years 2 Months | Current |
Peer comparison
Link Pharmachem Limited is compared with the 6 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Link Pharmachem Limitedthis company | ₹27.43 Cr (FY 2026) | ₹7 Lakh | 0.3% | 7.9% | 84 | Vadodara, Gujarat, India |
| SVK Laboratories Private Limited | ₹25.79 Cr (FY 2025) | 37.0% | Hyderabad, Telangana, India | |||
| Ever Health Life Sciences Private Limited | ₹25.78 Cr (FY 2022) | -38.0% | Vijayawada, Andhra Pradesh, India | |||
| Pharmanova Specialties Private Limited | ₹25.7 Cr (FY 2023) | 13.0% | Mumbai, Maharashtra, India | |||
| Jineka Healthcare Private Limited | ₹25.65 Cr (FY 2025) | -3.0% | Haridwar, Uttarakhand, India | |||
| Molclone Labs Private Limited | ₹25.57 Cr (FY 2025) | 12.0% | Chennai, Tamil Nadu, India | |||
| D R Johns Lab Private Limited | ₹25.41 Cr (FY 2025) | 60.0% | New Delhi, Delhi, India |
To see the full peer comparison of Link Pharmachem Limited, buy the company report.
Auditor
Link Pharmachem Limited is audited by CNK & Associates LLP for the financial year 2025.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| CNK & Associates LLP | FY 2025 | 101961W/W-100036 |
Shareholding
Shareholding for the quarter ended Mar 2026: promoters hold 52.40%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 47.60%.
Mar 2026
QUARTER
52.40% Promoters
47.60% Retail & Others
Promoter holding - history
Now 52.40% · Mar 2026High 52.40% · Mar 2026Low 51.50% · Jun 2025
Shareholding trend - last 6 quarters
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 52.40% | 51.50% | 51.50% | 51.50% |
| Public | 47.60% | 48.50% | 48.50% | 48.50% |
Charges & borrowings
Open charges
₹19.22 Cr
Satisfied charges
₹20.51 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 24 Nov 2006 | 10027597 | Bank of India | ₹9.61 Cr | Open | |
| 07 Oct 2006 | 10022267 | Bank of India | ₹9.61 Cr | Open | |
| 16 Jul 2016 | 100041470 | Others | ₹22.71 Lakh | Satisfied | |
| 16 Dec 2003 | 90102849 | State Bank of India | ₹2.23 Cr | Satisfied | |
| 28 Jul 2000 | 90102823 | State Bank of India | ₹3 Cr | Satisfied |
To see the full charge records of Link Pharmachem Limited, buy the company report.
Total charge records: 17 View all charges
Deals & funding
Link Pharmachem Limited has 12 deals on record (12 market trades); the latest was in March 2026.
Total deals
12
Market trades
12
Deals on record (5 of 12)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2026 | Market trade | ₹10.2 Lakh | Buyer: an individual Seller: an individual |
| Sep 2024 | Market trade | ₹12 Lakh | Seller: an individual |
| Aug 2024 | Market trade | ₹14.9 Lakh | Seller: an individual |
| Aug 2024 | Market trade | ₹10.4 Lakh | Seller: an individual |
| Jul 2023 | Market trade | ₹56.3 Lakh | Buyer: Bonanza Portfolio (Ifsc) Private Limited , an individual Seller: Bonanza Portfolio (Ifsc) Private Limited , 2 individuals |
To see the full deal history of Link Pharmachem Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Link Pharmachem Limited has 12 court cases on record: 6 filed by Link Pharmachem, 6 filed against it. 8 cases are pending and 4 are disposed.
Total cases
12
Filed by the company
6
Filed against the company
6
Pending
8
Disposed
4
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 11 | 5 | 8 |
| High courts | 1 | 1 | 0 |
Cases on record (5 of 12)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Vadodara, Gujarat | Court case (CR A) | Filed against the company by an individual | Pending |
| District court, Vadodara, Gujarat | Criminal complaint | Filed by the company against an individual | Pending |
| District court, Vadodara, Gujarat | Criminal complaint | Filed by the company against an individual | Pending |
| District court, Vadodara, Gujarat | Criminal complaint | Filed by the company against an individual | Pending |
| District court, Vadodara, Gujarat | Criminal complaint | Filed by the company against an individual | Pending |
To see the full case history of Link Pharmachem Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Link Pharmachem Limited has 15 MSME Form 1 returns on record between 2019 and 2024, listing 260 overdue payments to 31 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 31)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier | |||
| Prime Organics |
To see the full MSME payment records of Link Pharmachem Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Link Pharmachem Limited has a workforce of 84 employees on its EPFO records as of Dec 31, 2025, across 1 active EPFO establishment.
Employee count
84
Active EPFO establishments
1
Employee growth
-1.18%
GST
Link Pharmachem has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAACL3615M1ZL | Gujarat | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Link Pharmachem Limited, buy the company report.
Recent activity
Link Pharmachem Limited has 17 board changes on record since 1984: 11 appointments and 6 cessations. The latest: Devang Uttamchand Shah ceased to be Director on 27 Sep 2024.
Filing
Link Pharmachem Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Charges
A charge with Bank Of India of Rs. 9.61 Cr registered on 24 Nov 2006 with Charge ID 10027597 was modified on 16 Sep 2025.
AGM
Link Pharmachem Limited last Annual general meeting of members was held on 09 Sep 2025 as per latest MCA records.
Charges
A charge with Bank Of India of Rs. 9.61 Cr registered on 07 Oct 2006 with Charge ID 10022267 was modified on 18 Jul 2025.
Ceased
Devang Uttamchand Shah ceased to be Director.
Ceased
Suresh Balram Dhatrak ceased to be Director.
Appointed
Rangoli Saurav Gada was appointed as Director.
Appointed
Rohit Jitendraprasad Shah was appointed as Director.
Charges
A charge registered on 16 Jul 2016 via Charge ID 100041470 with Others was fully satisfied on 03 Jun 2024.
Ceased
Jayesh Pushpavadan Jani ceased to be CFO.
Appointed
Jayesh Pushpavadan Jani was appointed as CFO.
Appointed
Rachna Manav Ghai was appointed as Director.
51 earlier events are in the company report.
News
Frequently asked questions
Link Pharmachem is an active public limited company based in Vadodara, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 28 December 1984 (42+ years old) and is registered under CIN L24230GJ1984PLC007540. Listed on BSE: 524748.
Link Pharmachem reported revenue of ₹27.43 Cr for FY 2025-26 (up 7.9% YoY) based on standalone financials.
Link Pharmachem has 5 current directors:
- Rishikesh Satish Thakur - Managing Director
- Satish Ganpatrao Thakur - Whole-Time Director
- Rachna Manav Ghai - Director
- Rohit Jitendraprasad Shah - Director
- Rangoli Saurav Gada - Director
The latest financial statements of Link Pharmachem on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 09 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Link Pharmachem is 24AAACL3615M1ZL, registered in Gujarat.
The CIN (Corporate Identification Number) of Link Pharmachem is L24230GJ1984PLC007540. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Link Pharmachem is a listed company as per MCA records. Its shares are listed on BSE (code: 524748).
Link Pharmachem has 12 court cases on record: 6 filed by the company and 6 filed against it. 8 are pending. Most are in the district courts.
Link Pharmachem was incorporated on 28 December 1984, making it 42+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Link Pharmachem has 12 deals on record (12 market trades); the latest was in March 2026.
The peers of Link Pharmachem by revenue are SVK Laboratories Private Limited, Ever Health Life Sciences Private Limited, Pharmanova Specialties Private Limited, Jineka Healthcare Private Limited, Molclone Labs Private Limited and 1 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Devang Uttamchand Shah ceased to be Director on 27 Sep 2024. Suresh Balram Dhatrak ceased to be Director on 27 Sep 2024. Rangoli Saurav Gada was appointed as Director on 09 Aug 2024. Link Pharmachem has 17 board changes on record in total.